Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-046307
Filing Date
2024-11-07
Accepted
2024-11-07 16:22:35
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q espr-20240930.htm   iXBRL 10-Q 1147698
2 EX-31.1 espr-ex311x09302024.htm EX-31.1 10930
3 EX-31.2 espr-ex312x09302024.htm EX-31.2 10999
4 EX-32.1 espr-ex321x09302024.htm EX-32.1 8286
  Complete submission text file 0001628280-24-046307.txt   6954828

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20240930.xsd EX-101.SCH 64407
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT espr-20240930_cal.xml EX-101.CAL 52619
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT espr-20240930_def.xml EX-101.DEF 310861
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20240930_lab.xml EX-101.LAB 721848
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20240930_pre.xml EX-101.PRE 516825
76 EXTRACTED XBRL INSTANCE DOCUMENT espr-20240930_htm.xml XML 779550
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35986 | Film No.: 241436194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)